133 related articles for article (PubMed ID: 9040801)
1. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Nakamori S; Tateishi R
J Surg Oncol; 1997 Jan; 64(1):48-54. PubMed ID: 9040801
[TBL] [Abstract][Full Text] [Related]
2. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases.
Anton RC; Brown RW; Younes M; Gondo MM; Stephenson MA; Cagle PT
Hum Pathol; 1997 Sep; 28(9):1079-82. PubMed ID: 9308733
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.
Li Y; Xu KP; Jiang D; Zhao J; Ge JF; Zheng SY
Int J Clin Exp Pathol; 2015; 8(11):13978-86. PubMed ID: 26823709
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
[TBL] [Abstract][Full Text] [Related]
5. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis.
Poleri C; Morero JL; Nieva B; Vázquez MF; Rodríguez C; de Titto E; Rosenberg M
Chest; 2003 Jun; 123(6):1858-67. PubMed ID: 12796161
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status.
Dosaka-Akita H; Katabami M; Hommura H; Fujioka Y; Katoh H; Kawakami Y
Oncology; 1999 Apr; 56(3):259-64. PubMed ID: 10202283
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.
Laudanski J; Niklinska W; Burzykowski T; Chyczewski L; Niklinski J
Eur Respir J; 2001 Apr; 17(4):660-6. PubMed ID: 11401061
[TBL] [Abstract][Full Text] [Related]
11. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
13. Biological prognostic factors for early stage completely resected non-small cell lung cancer.
Cagini L; Monacelli M; Giustozzi G; Moggi L; Bellezza G; Sidoni A; Bucciarelli E; Darwish S; Ludovini V; Pistola L; Gregorc V; Tonato M
J Surg Oncol; 2000 May; 74(1):53-60. PubMed ID: 10861611
[TBL] [Abstract][Full Text] [Related]
14. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated "lymphoepithelioma-like" carcinoma as a distinct entity with better prognosis.
Chen FF; Yan JJ; Lai WW; Jin YT; Su IJ
Cancer; 1998 Jun; 82(12):2334-42. PubMed ID: 9635525
[TBL] [Abstract][Full Text] [Related]
16. Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers.
Dosaka-Akita H; Miyoshi E; Suzuki O; Itoh T; Katoh H; Taniguchi N
Clin Cancer Res; 2004 Mar; 10(5):1773-9. PubMed ID: 15014031
[TBL] [Abstract][Full Text] [Related]
17. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma.
Ritter JH; Dresler CM; Wick MR
Hum Pathol; 1995 Nov; 26(11):1227-32. PubMed ID: 7590697
[TBL] [Abstract][Full Text] [Related]
18. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.
Lai RS; Wang JS; Hsu HK; Chang HC; Lin CH; Lin MH
Jpn J Clin Oncol; 2002 Oct; 32(10):393-7. PubMed ID: 12451034
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases.
Kren L; Brazdil J; Hermanova M; Goncharuk VN; Kallakury BV; Kaur P; Ross JS
Appl Immunohistochem Mol Morphol; 2004 Mar; 12(1):44-9. PubMed ID: 15163019
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
Lee JS; Yoon A; Kalapurakal SK; Ro JY; Lee JJ; Tu N; Hittelman WN; Hong WK
J Clin Oncol; 1995 Aug; 13(8):1893-903. PubMed ID: 7636531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
